MARK DAVIS: Open Payments
NPI 1679580435 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$227,035 in 523 payments from 43 companies in 2025. Trend: 2023 $150,584 · 2024 $219,155 · 2025 $227,035
Speaker / faculty: $148,583Travel & lodging: $55,480Consulting: $13,087Food & beverage: $9,524Education: $362
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 79 | $44,748 |
| JAZZ PHARMACEUTICALS INC. | 91 | $38,708 |
| SOBI, INC | 57 | $34,036 |
| GlaxoSmithKline, LLC. | 43 | $32,235 |
| Geron Corporation | 25 | $19,288 |
| Incyte Corporation | 62 | $19,106 |
| Regeneron Healthcare Solutions, Inc. | 40 | $12,764 |
| E.R. Squibb & Sons, L.L.C. | 16 | $5,728 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $4,843 |
| AstraZeneca Pharmaceuticals LP | 17 | $4,246 |
Products named: RYBREVANT, ZIIHERA, OJJAARA, Vonjo, RYTELO, Monjuvi, LIBTAYO, REBLOZYL.
Industry payments across TX — which companies pay providers there.
